Evommune's stock opened under pressure after the company announced that EVO756 failed to reach both primary and secondary endpoints in a Phase 2b trial testing the drug in adults with moderate-to-severe atopic dermatitis. In pre-open trading the shares were down 13.9% to $11.26 following the disclosure.
The randomized, double-blind, placebo-controlled Phase 2b study enrolled 121 adults who were treated over a 12-week period. The trial did not achieve its primary endpoint - the percent change in Eczema Area and Severity Index score from baseline at Week 12 - across any of the doses evaluated. In light of the result, Evommune said it will not continue development of EVO756 for atopic dermatitis.
Evommune will, however, continue development of EVO756 in a Phase 2b program for migraine prophylaxis. The company also retains EVO301, an IL-18 binding protein fusion candidate that is in Phase 2b development for atopic dermatitis and ulcerative colitis, as a key asset in its pipeline.
The latest atopic dermatitis failure is the second consecutive Phase 2b setback for EVO756 this year. Earlier in 2026 the compound failed to meet its primary endpoint in a chronic spontaneous urticaria trial, a result that led Evommune to discontinue that program and prompted William Blair to downgrade the stock to Market Perform.
Investor sentiment has been further strained by a reported pattern of insider stock sales by senior executives in the months surrounding these clinical setbacks. Amid these company-specific headwinds, Evercore ISI maintained a Buy rating on the stock today, while broader analyst views have remained divided.
The wider U.S. equity market provided little support for Evommune's shares. The S&P 500, Dow Jones, and Nasdaq were all trading in negative territory in pre-market trading, reflecting a cautious macro backdrop that amplified pressure on the stock.
Market reaction pushed the shares toward their 52-week low of $10.47, a sharp contrast with the 52-week high of $33.20 and an indication of how heavily the company’s market value had been tied to EVO756’s potential in inflammatory skin disease. With EVO756’s two largest near-term indications now shelved, the market’s assessment of Evommune will increasingly depend on EVO301 and the newly initiated migraine prophylaxis study.
What happened
EVO756 missed primary and secondary endpoints in a Phase 2b atopic dermatitis trial enrolling 121 adults over 12 weeks. The company will not pursue the drug for atopic dermatitis but plans to continue development in migraine prophylaxis.
Why it matters
The result is the second Phase 2b failure for EVO756 this year, following a separate miss in chronic spontaneous urticaria that led to discontinuation of that program and a William Blair downgrade. Insider sales activity and a risk-off market environment intensified selling pressure.
What’s next
Evommune’s near-term valuation case now places greater weight on EVO301 and the migraine prophylaxis program. Analyst opinions are mixed, with Evercore ISI maintaining a Buy rating while other firms remain divided.